Loading...
LMNL logo

Liminal BioSciences Inc.NasdaqCM:LMNL 株式レポート

時価総額 US$13.1m
株価
n/a
私の公正価値
n/a
1Y87.1%
7D0.4%
1D
ポートフォリオ価値
​
表示

Liminal BioSciences Inc.

NasdaqCM:LMNL 株式レポート

時価総額：US$13.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Liminal BioSciences（LMNL）株式概要

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. 詳細

LMNL ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長0/6
過去の実績0/6
財務の健全性4/6
配当金0/6

報酬

過去5年間の収益は年間41%増加しました。

リスク分析

キャッシュランウェイが1年未満である

収益が 100 万ドル未満 ( CA$492K )

US市場と比較した過去 3 か月間の株価の変動

過去1年間で株主の希薄化が進んだ

+1 さらなるリスク

LMNL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Liminal BioSciences Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Liminal BioSciences
過去の株価
現在の株価€8.50
52週高値€8.50
52週安値€3.10
ベータ29.34
1ヶ月の変化0.95%
3ヶ月変化35.35%
1年変化87.10%
3年間の変化-92.36%
5年間の変化-99.75%
IPOからの変化-99.24%

最新ニュース

Seeking Alpha • Sep 02

Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule

Liminal BioSciences (NASDAQ:LMNL) received approval from the Qualifications Department of The Nasdaq Stock Market to transfer its common shares from the Nasdaq Global Market to the Nasdaq Capital Market. The Canadian company said its shares will begin trading on the Nasdaq Capital Market on Sept. 6 and will continue to trade under the symbol "LMNL". Liminal noted that in March 4, it received a notice from Nasdaq for not being in compliance with the exchange's minimum bid price rule of $1.00 per share for continued listing on the exchange. The company had then been granted 180 days to comply with the rule and now with the transfer to the Nasdaq Capital Market, Nasdaq has granted a second period of 180 calendar days or until Feb. 27, 2023, to regain compliance. Liminal said that it may implement a reverse stock split, if necessary, to regain compliance.
Seeking Alpha • Aug 25

Liminal BioSciences ends CDMO agreement for $33M cost savings

Canadian biotech Liminal BioSciences (NASDAQ:LMNL) announced Thursday that the company terminated the long-term legacy CDMO agreement relating to its previously owned plasma-derived therapeutics business in favor of ~$33.1M cash savings. The deal signed in May 2021 included a $9M minimum purchase commitment per year for the remaining contract period. Previously, LMNL had sent an early five-year termination notice to end the agreement in August 2021. The termination agreement ends the deal with immediate effect, and per the terms, LMNL will pay $18M to cover past sums due to the termination date. Additional two payments worth $3.4M each are due in Q1 2023 and Q1 2024. "We are very pleased to have reached this agreement, which results in anticipated cash savings of approximately $33.1 million," Chief Executive Bruce Pritchard remarked. In October, LMNL announced the complete divestment of its plasma-derived therapeutics business for more than $100M.

Recent updates

Seeking Alpha • Sep 02

Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule

Liminal BioSciences (NASDAQ:LMNL) received approval from the Qualifications Department of The Nasdaq Stock Market to transfer its common shares from the Nasdaq Global Market to the Nasdaq Capital Market. The Canadian company said its shares will begin trading on the Nasdaq Capital Market on Sept. 6 and will continue to trade under the symbol "LMNL". Liminal noted that in March 4, it received a notice from Nasdaq for not being in compliance with the exchange's minimum bid price rule of $1.00 per share for continued listing on the exchange. The company had then been granted 180 days to comply with the rule and now with the transfer to the Nasdaq Capital Market, Nasdaq has granted a second period of 180 calendar days or until Feb. 27, 2023, to regain compliance. Liminal said that it may implement a reverse stock split, if necessary, to regain compliance.
Seeking Alpha • Aug 25

Liminal BioSciences ends CDMO agreement for $33M cost savings

Canadian biotech Liminal BioSciences (NASDAQ:LMNL) announced Thursday that the company terminated the long-term legacy CDMO agreement relating to its previously owned plasma-derived therapeutics business in favor of ~$33.1M cash savings. The deal signed in May 2021 included a $9M minimum purchase commitment per year for the remaining contract period. Previously, LMNL had sent an early five-year termination notice to end the agreement in August 2021. The termination agreement ends the deal with immediate effect, and per the terms, LMNL will pay $18M to cover past sums due to the termination date. Additional two payments worth $3.4M each are due in Q1 2023 and Q1 2024. "We are very pleased to have reached this agreement, which results in anticipated cash savings of approximately $33.1 million," Chief Executive Bruce Pritchard remarked. In October, LMNL announced the complete divestment of its plasma-derived therapeutics business for more than $100M.
Seeking Alpha • Jul 21

Liminal BioSciences discontinues fezagepras development

Liminal BioSciences (NASDAQ:LMNL) said Thursday it discontinued development of fezagepras. The decision is based on results from the phase 1a single ascending dose clinical trial, which showed that fezagepras was significantly inferior to sodium phenylbutyrate as a nitrogen scavenger. The clinical trial, which began in May, was designed as a head-to-head comparison with sodium phenylbutyrate to evaluate whether fezagepras was worth developing. The decision to stop fezagepras' development was not based on safety concerns.

株主還元

LMNLUS BiotechsUS 市場
7D0.4%-1.6%-0.8%
1Y87.1%34.4%27.1%

業界別リターン: LMNL過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: LMNL過去 1 年間で27.1 % の収益を上げたUS市場を上回りました。

価格変動

Is LMNL's price volatile compared to industry and market?
LMNL volatility
LMNL Average Weekly Movement11.7%
Biotechs Industry Average Movement11.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

安定した株価: LMNLの株価は、 US市場と比較して過去 3 か月間で変動しています。

時間の経過による変動: LMNLの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
1994n/aBruce Pritchardwww.liminalbiosciences.com

Liminal BioSciences Inc. 基礎のまとめ

Liminal BioSciences の収益と売上を時価総額と比較するとどうか。
LMNL 基礎統計学
時価総額US$13.05m
収益（TTM）-US$28.06m
売上高(TTM)US$492.00k
0.0x
P/Sレシオ
0.0x
PER（株価収益率

LMNL は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
LMNL 損益計算書（TTM）
収益CA$492.00k
売上原価CA$15.49m
売上総利益-CA$15.00m
その他の費用CA$13.06m
収益-CA$28.06m

直近の収益報告

Jun 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）-8.63
グロス・マージン-3,048.17%
純利益率-5,702.85%
有利子負債／自己資本比率0%

LMNL の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/09/27 02:01
終値2023/09/25 00:00
収益2023/06/30
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Liminal BioSciences Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12

アナリスト機関
Doug CooperBeacon Securities Limited
Antonia BorovinaBloom Burton & Co.
Dewey SteadmanCanaccord Genuity